Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -7.14%7.51B | -6.38%1.79B | -7.52%1.85B | -3.56%1.99B | -10.99%1.87B | -0.76%8.09B | -4.96%1.91B | -1.04%2.01B | 1.80%2.07B | 1.07%2.1B |
Cost of revenue | -5.84%5.71B | -2.09%1.39B | -6.43%1.39B | -4.61%1.5B | -9.86%1.43B | -4.10%6.06B | -21.79%1.42B | 0.09%1.49B | 3.84%1.58B | 5.08%1.58B |
Gross profit | -11.05%1.8B | -18.83%396.85M | -10.63%464.03M | -0.21%491.16M | -14.43%445.24M | 10.83%2.02B | 153.41%488.91M | -4.16%519.24M | -4.22%492.21M | -9.45%520.31M |
Operating expense | 7.77%1.36B | 11.19%333.46M | 4.48%335.13M | 9.68%343.37M | 6.01%345.59M | -2.65%1.26B | -3.63%299.9M | 0.42%320.75M | -4.84%313.08M | -2.50%325.99M |
Operating profit | -42.21%439.73M | -66.46%63.39M | -35.06%128.9M | -17.50%147.79M | -48.72%99.65M | 43.78%760.94M | 259.82%189M | -10.72%198.49M | -3.12%179.13M | -19.13%194.32M |
Net non-operating interest income (expenses) | 13.28%-42.96M | 40.84%-3.48M | 5.93%-12.76M | 11.42%-13.19M | 10.98%-13.53M | 15.67%-49.54M | 27.43%-5.89M | 14.82%-13.56M | 12.37%-14.89M | 14.23%-15.2M |
Non-operating interest income | 5.54%9.6M | 7.35%9.34M | -85.90%54K | 2,366.67%148K | 5,100.00%52K | 11.06%9.09M | 9.03%8.7M | 732.61%383K | -94.96%6K | -97.50%1K |
Non-operating interest expense | -10.36%52.56M | -12.09%12.83M | -8.12%12.81M | -10.47%13.34M | -10.64%13.58M | -12.40%58.63M | -9.35%14.59M | -12.66%13.95M | -12.94%14.9M | -14.42%15.2M |
Net investment income | 631.28%5.25M | 75.17%-1.59M | 194.98%3.88M | -8.68%2.66M | -95.44%300K | 35.59%-988K | -79.14%-6.4M | -363.35%-4.08M | 40.50%2.91M | 514.82%6.58M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -60.32%-6.26M | -137.42%-1.37M | -17,436.84%-3.33M | 90.96%-634K | -77.44%-928K | 99.29%-3.9M | 100.77%3.65M | 99.51%-19K | 89.61%-7.01M | -523K |
Less:Other special charges | 138.46%1.67M | 104.59%200K | --1.24M | ---- | ---- | -118.38%-4.35M | ---4.36M | --0 | ---- | ---- |
Less:Write off | -44.38%4.59M | 64.78%1.17M | 10,915.79%2.09M | -94.26%402K | 77.44%928K | -98.43%8.25M | -99.84%707K | -99.51%19K | --7M | --523K |
Other non-operating income (expenses) | -232.31%-20.09M | -667.13%-35.61M | -125.35%-689K | -8.51%16.5M | 68.15%-294K | -5.35%15.19M | -131.75%-4.64M | 523.39%2.72M | -0.81%18.03M | -61.93%-923K |
Income before tax | -47.95%375.67M | -87.85%21.34M | -36.80%116M | -14.06%153.12M | -53.76%85.2M | 1,246.05%721.7M | 128.88%175.72M | -10.24%183.54M | 47.66%178.18M | -16.40%184.26M |
Income tax | -57.92%86.01M | -121.64%-10.61M | -36.91%32.04M | -15.69%42.76M | -59.46%21.83M | 156.06%204.39M | 143.62%49.04M | -21.55%50.79M | -16.66%50.72M | -19.24%53.85M |
Net income | -44.01%289.65M | -74.78%31.96M | -36.75%83.96M | -13.42%110.36M | -51.40%63.38M | 462.28%517.31M | 125.54%126.68M | -5.00%132.75M | 113.10%127.47M | -15.17%130.41M |
Net income continuous operations | -44.01%289.65M | -74.78%31.96M | -36.75%83.96M | -13.42%110.36M | -51.40%63.38M | 462.28%517.31M | 125.54%126.68M | -5.00%132.75M | 113.09%127.47M | -15.17%130.41M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | -44.01%289.65M | -74.78%31.96M | -36.75%83.96M | -13.42%110.36M | -51.40%63.38M | 462.28%517.31M | 125.54%126.68M | -5.00%132.75M | 113.10%127.47M | -15.17%130.41M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -44.01%289.65M | -74.78%31.96M | -36.75%83.96M | -13.42%110.36M | -51.40%63.38M | 462.28%517.31M | 125.54%126.68M | -5.00%132.75M | 113.10%127.47M | -15.17%130.41M |
Gross dividend payment | ||||||||||
Basic earnings per share | -44.00%228.42 | -74.76%25.21 | -36.75%66.21 | -13.40%87.03 | -51.40%49.97 | 462.38%407.89 | 125.55%99.9 | -4.98%104.68 | 113.10%100.5 | -15.15%102.81 |
Diluted earnings per share | -44.00%228.42 | -74.77%25.2042 | -36.74%66.21 | -13.40%87.0278 | -51.40%49.97 | 462.38%407.89 | 125.54%99.8956 | -4.98%104.6575 | 113.14%100.4903 | -15.15%102.81 |
Dividend per share | 0.00%50 | 0.00%50 | 0 | 0 | 0 | 0.00%50 | 0.00%50 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |